A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Rocbrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Lupeng Pharmaceutical
Most Recent Events
- 25 Mar 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 15 Apr 2024 Status changed from not yet recruiting to recruiting.
- 16 Feb 2024 New trial record